Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy |
Cho, Jaewon
(Department of Pharmacy, Kangwon National University)
Tae, Nara (Kangwon Institute of Inclusive Technology, Kangwon National University) Ahn, Jae-Hee (Department of Pharmacy, Kangwon National University) Chang, Sun-Young (College of Pharmacy, Ajou University) Ko, Hyun-Jeong (Department of Pharmacy, Kangwon National University) Kim, Dae Hee (Department of Pharmacy, Kangwon National University) |
1 | Moon, E. K., Carpenito, C., Sun, J., Wang, L. C., Kapoor, V., Predina, J., Powell, D. J., Jr., Riley, J. L., June, C. H. and Albelda, S. M. (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719-4730. DOI |
2 | Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., McSweeney, P., Munoz, J., Avivi, I., Castro, J. E., Westin, J. R., Chavez, J. C., Ghobadi, A., Komanduri, K. V., Levy, R., Jacobsen, E. D., Witzig, T. E., Reagan, P., Bot, A., Rossi, J., Navale, L., Jiang, Y., Aycock, J., Elias, M., Chang, D., Wiezorek, J. and Go, W. Y. (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531-2544. |
3 | Moon, E. K., Wang, L. C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Pure, E., Milone, M. C., June, C. H., Riley, J. L., Wherry, E. J. and Albelda, S. M. (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin. Cancer Res. 20, 4262-4273. DOI |
4 | Principe, N., Kidman, J., Goh, S., Tilsed, C. M., Fisher, S. A., Fear, V. S., Forbes, C. A., Zemek, R. M., Chopra, A., Watson, M., Dick, I. M., Boon, L., Holt, R. A., Lake, R. A., Nowak, A. K., Lesterhuis, W. J., McDonnell, A. M. and Chee, J. (2020) Tumor infiltrating effector memory antigen-specific CD8(+) T cells predict response to immune checkpoint therapy. Front. Immunol. 11, 584423. |
5 | Qin, S., Xu, L., Yi, M., Yu, S., Wu, K. and Luo, S. (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155. |
6 | Teoh, P. J. and Chng, W. J. (2021) CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 11, 84. |
7 | Turtle, C. J., Hay, K. A., Hanafi, L. A., Li, D., Cherian, S., Chen, X., Wood, B., Lozanski, A., Byrd, J. C., Heimfeld, S., Riddell, S. R. and Maloney, D. G. (2017) Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 35, 3010-3020. DOI |
8 | Waldman, A. D., Fritz, J. M. and Lenardo, M. J. (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651-668. DOI |
9 | Zhang, C., Liu, J., Zhong, J. F. and Zhang, X. (2017) Engineering CAR-T cells. Biomarker Res. 5, 22. |
10 | Yu, W. L. and Hua, Z. C. (2019) Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: efficacy and safety-a systematic review with meta-analysis. Cancers (Basel) 11, 47. |
11 | Newick, K., O'Brien, S., Moon, E. and Albelda, S. M. (2017) CAR T cell therapy for solid tumors. Annu. Rev. Med. 68, 139-152. DOI |
12 | Edeline, J., Houot, R., Marabelle, A. and Alcantara, M. (2021) CAR-T cells and BiTEs in solid tumors: challenges and perspectives. J. Hematol. Oncol. 14, 65. |
13 | Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., Raubitschek, A., Forman, S. J., Greenberg, P. D., Riddell, S. R. and Press, O. W. (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119, 3940-3950. DOI |
14 | You, G., Won, J., Lee, Y., Moon, D., Park, Y., Lee, S. H. and Lee, S. W. (2021) Bispecific antibodies: a smart arsenal for cancer immunotherapies. Vaccines 9, 724. |
15 | Zheng, P. P., Kros, J. M. and Li, J. (2018) Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today 23, 1175-1182. DOI |
16 | Choi, J. R., Kim, M. J., Tae, N., Wi, T. M., Kim, S. H., Lee, E. S. and Kim, D. H. (2020) BLI-based functional assay in phage display benefits the development of a PD-L1-targeting therapeutic antibody. Viruses 12, 684. |
17 | Chung, Y., Kim, B. S., Kim, Y. J., Ko, H. J., Ko, S. Y., Kim, D. H. and Kang, C. Y. (2006) CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res. 66, 6843-6850. DOI |
18 | Ahn, J. H., Lee, B. H., Kim, S. E., Kwon, B. E., Jeong, H., Choi, J. R., Kim, M. J., Park, Y., Kim, B. S., Kim, D. H. and Ko, H. J. (2021) A novel anti-PD-L1 antibody exhibits antitumor effects on multiple myeloma in murine models via antibody-dependent cellular cytotoxicity. Biomol. Ther. (Seoul) 29, 166-174. DOI |
19 | Alegre, M. L., Tso, J. Y., Sattar, H. A., Smith, J., Desalle, F., Cole, M. and Bluestone, J. A. (1995) An anti-murine CD3 monoclonal anti-body with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155, 1544-1555. DOI |
20 | Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., Oak, J. S., Younes, S. F., Ozawa, M. G., Yang, E., Natkunam, Y., Tamaresis, J., Ehlinger, Z., Reynolds, W. D., Arai, S., Johnston, L., Lowsky, R., Meyer, E., Negrin, R. S., Rezvani, A. R., Shiraz, P., Sidana, S., Weng, W. K., Davis, K. L., Ramakrishna, S., Schultz, L., Mullins, C., Jacob, A., Kirsch, I., Feldman, S. A., Mackall, C. L., Miklos, D. B. and Muffly, L. (2021) CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood 137, 2321-2325. |
21 | Li, Y. and Kurlander, R. J. (2010) Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J. Transl. Med. 8, 104. |
22 | Kershaw, M. H., Westwood, J. A. and Darcy, P. K. (2013) Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13, 525-541. DOI |
23 | Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., Chen, C. C., Yang, J. C., Rosenberg, S. A. and Hwu, P. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115. DOI |
24 | Ko, H. J., Kim, Y. J., Kim, Y. S., Chang, W. S., Ko, S. Y., Chang, S. Y., Sakaguchi, S. and Kang, C. Y. (2007) A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67, 7477-7486. DOI |
25 | Liu, Q., Sun, Z. and Chen, L. (2020) Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell 11, 549-564. DOI |
26 | Horn, L. A., Ciavattone, N. G., Atkinson, R., Woldergerima, N., Wolf, J., Clements, V. K., Sinha, P., Poudel, M. and Ostrand-Rosenberg, S. (2017) CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget 8, 57964-57980. DOI |
27 | Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A. and Grupp, S. A. (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439-448. |
28 | Franquiz, M. J. and Short, N. J. (2020) Blinatumomab for the treatment of adult B-cell acute lymphoblastic leukemia: toward a new era of targeted immunotherapy. Biol. Targets Ther. 14, 23-34. DOI |
29 | Geuijen, C., Tacken, P., Wang, L. C., Klooster, R., van Loo, P. F., Zhou, J., Mondal, A., Liu, Y. B., Kramer, A., Condamine, T., Volgina, A., Hendriks, L. J. A., van der Maaden, H., Rovers, E., Engels, S., Fransen, F., den Blanken-Smit, R., Zondag-van der Zande, V., Basmeleh, A., Bartelink, W., Kulkarni, A., Marissen, W., Huang, C. Y., Hall, L., Harvey, S., Kim, S., Martinez, M., O'Brien, S., Moon, E., Albelda, S., Kanellopoulou, C., Stewart, S., Nastri, H., Bakker, A. B. H., Scherle, P., Logtenberg, T., Hollis, G., de Kruif, J., Huber, R., Mayes, P. A. and Throsby, M. (2021) A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat. Commun. 12, 4445. |
30 | Jeong, S., Park, E., Kim, H. D., Sung, E., Kim, H., Jeon, J., Kim, Y., Jung, U. J., Son, Y. G., Hong, Y., Lee, H., Lee, S., Lim, Y., Won, J., Jeon, M., Hwang, S., Fang, L., Jiang, W., Wang, Z., Shin, E. C., Park, S. H. and Jung, J. (2021) Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J. Immunother. Cancer 9, e002428. |
31 | Jiang, H., Ni, H., Zhang, P., Guo, X., Wu, M., Shen, H., Wang, J., Wu, W., Wu, Z., Ding, J., Tang, R., Zhou, S., Chen, B., Yu, M., Jing, H. and Liu, J. (2021) PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Oncoimmunology 10, 1943180. |